Loading...
•
Dec 31, 2023
Lyra Q4 2023 Earnings Report
Reported financial results for Q4 and full year 2023 and provided a corporate update.
Key Takeaways
Lyra Therapeutics reported its Q4 and full year 2023 financial results, highlighting upcoming milestones for their product candidates LYR-210 and LYR-220, including topline results from the ENLIGHTEN I Phase 3 trial expected in Q2 2024. The company's cash runway is projected into the first quarter of 2025.
Topline results from ENLIGHTEN I pivotal Phase 3 clinical trial of LYR-210 are expected in Q2 2024.
Enrollment in ENLIGHTEN II, the second pivotal Phase 3 clinical trial of LYR-210, is expected to be completed in the second half of 2024.
Results from ENLIGHTEN I 52-week extension study are expected in Q4 2024.
An end-of-Phase 2 meeting for LYR-220 with the FDA is scheduled for the second half of 2024.
Revenue by Segment
Forward Guidance
Lyra Therapeutics anticipates several milestones in 2024, focusing on clinical trial results and regulatory interactions.
Positive Outlook
- Reporting topline results from ENLIGHTEN I pivotal Phase 3 clinical trial of LYR-210 in Q2 2024.
- Completing enrollment in ENLIGHTEN II, the second pivotal Phase 3 clinical trial of LYR-210, in the second half of 2024.
- Reporting results from ENLIGHTEN I 52-week extension study in Q4 2024.
- Having an end of Phase 2 meeting for LYR-220 with the U.S. Food and Drug Administration (FDA) in the second half of 2024.
- Management believes its existing cash, cash equivalents and short-term investments balance are sufficient to fund the Company’s planned operations into the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...